Table 1.
Deregulated Hypoxamirs and Physiopathological Role
| miR | Biological effect/disease | Modulation | Tissue/cell | EFF | SMs | References |
|---|---|---|---|---|---|---|
| Let-7 | Angiogenesis | Up | EC | HIF1A | (27) | |
| miR-1 | Hypoxia | Up | CM | p38 MAPK | Tanshinone IIA | (160) |
| miR-1 | IPC (Mm) | Up | CM | nd | (120) | |
| miR-103 | Angiogenesis | Up | EC | HIF1A | (27) | |
| miR-107 | Angiogenesis | Up | EC | HIF1A | (27) | |
| miR-107 | Angiog/prolif | Up | CoCs | p53 | 102 | |
| miR-127 | Adhesion | Up | RC | HIF1A | (2) | |
| miR-132 | Angiogenesis | Up | EP | nd | (67) | |
| miR-185 | Angiogenesis | Up | EC | nd | (58) | |
| miR-199a | MI/CI (Mm) | Down | CM/brain | nd | 3-NPA | (117, 149) |
| miR-200b | Angiogenesis | Down | EC | nd | H2O2, BCNU | (22, 91) |
| miR-200c | Apopt/senescence | Down | EC/hUCB-MSCs | nd | 5-AzaC | (91, 130) |
| miR-21 | IP (Mm) | Up | CM | nd | (29) | |
| miR-21 | WH | Up | Skin | nd | (90, 104) | |
| miR-21 | Inflammation | Up | MØ | nd | (89) | |
| miR-21 | PH | Up | Lung | AKT2 | (103) | |
| miR-21 | PH | Down | Lung | TGF-β | (19) | |
| miR-21 | HF (Mm) | Down | Heart | AKT | (122) | |
| miR-21 | MI (Mm) | Down | CM | AKT | (122) | |
| miR-210 | MI | Up | Heart | nd | (12) | |
| miR-210 | MI (Mm) | Up | Heart | nd | (59) | |
| miR-210 | HF | Up | Heart | nd | (52) | |
| miR-210 | THR | Up | mSC | nd | (70) | |
| miR-210 | Hypoxia | Up | CM | AKT | (99) | |
| miR-210 | CI (Mm) | Up | Brain | nd | (88, 110) | |
| miR-210 | Stroke | Down | Blood | nd | (159) | |
| miR-210 | AO | Up | Blood | nd | (78) | |
| miR-210 | Kidney injury | Down | Blood | nd | (85) | |
| miR-210 | I/R (Mm) | Up | Kidney | nd | (80) | |
| miR-210 | IWH (Mm) | Up | Skin | HIF1A | (9) | |
| miR-210 | Angiogenesis | Up | EC | nd | WSS25 | (40, 80, 87, 147) |
| miR-210 | SC survival (Mm)/apoptosis/preclampsia | Up | PmSC/CNE/Trophoblast cells | HIF1A | DFOM | (57, 69, 98) |
| miR-210 | Proliferation | Up | Lung cancer | HIF1A | EGCG | (141) |
| miR-24 | Angiogenesis | Up | EC | nd | (45) | |
| miR-322 | MI (Mm) | Up | Heart | HIF1A | (48) | |
| miR-34a | Chronic hypoxia | Down | RC/EPC CAD | HIF1A | Atorvastatin | (38, 131) |
| miR-34a | MI (Mm) | Up | BM cells | nd | (148) | |
| miR-378 | MI (Mm) | Down | Heart | nd | (39) | |
| miR-378 | Apoptosis | Down | CM | nd | (39) | |
| miR-424 | Angiogenesis | Up | EC | SPI1/PU.1 | (48) | |
| miR-484 | MI (Mm) | Down | CM | FOXO3A | (142) |
3-NPA, nitropropionic acid; 5-AzaC, 5-azacytidine; AO, atherosclerosis obliterans; BCNU, 1,3-bis(2 chloroethyl)-1-nitrosourea; BM, bone marrow; CI, cerebral ischemia; CM, cardiomyocytes; CNE, nasopharyngeal carcinoma cells; CoCs, colon cancer cells; DFOM, deferoxamine mesylate; EC, endothelial cells; EGCG, epigallocatechin-3-gallate; EFF, effector (transcription factor/signaling pathway); EP, endothelial pericytes; EPC CAD, endothelial precursor cells from CAD patients; HF, heart failure; FOXO3A, forkhead box O3; hUCB-MSCs, human umbilical cord blood-derived multipotent stem cells; hypoxamiR, hypoxia-induced miRNA; IP, ischemic preconditioning; I/R, ischemia–reperfusion; IWH, ischemic wound healing; MI, myocardial infarction; Mm, mus musculus; MØ, macrophages; PH, pulmonary hypertension; PmSC, preconditioned mesenchymal stem cells; RC, renal cells; SC, stem cells; SMs, small molecules; THR, transplanted heart recovery; WH, wound healing.